MANCHESTER ROYAL INFIRMARY
Department of Neurology Oxford Road, Manchester M13 9WL Tel: 0161 276
1234
STRICTLY CONFIDENTIAL CLINIC LETTER - NEUROLOGY
NHS #: 789 456 1230 Date: 24 February 2025 Hosp #: MRI45678 Consul-
tant: Dr. Michael Chen
PATIENT: JONES, Sarah DOB: 05/04/1990 (34y) GP: Dr. P. Thompson
Address: 15 Deansgate Ln Surgery: Chorlton Health Centre Manchester M3
4NT
RE: RELAPSING REMITTING MULTIPLE SCLEROSIS -
FOLLOW-UP
Diagnosis: Relapsing Remitting Multiple Sclerosis (diagnosed 2022)
Background: Ms. Jones was diagnosed with RRMS following episodes of
right optic neuritis and left-sided sensory disturbance in 2022. McDonald
criteria fulfilled with MRI showing dissemination in time and space. Started on
ocrelizumab in August 2022 with good disease control until recent symptoms.
Current Presentation: Reports 2-week history of increased fatigue and new
onset of numbness in right leg. No visual symptoms, weakness, or sphincter
disturbance. Last ocrelizumab infusion 5 months ago.
Current Medications: - Ocrelizumab 600mg IV every 6 months - Amitriptyline
10mg nocte for neuropathic pain - Modafinil 100mg morning PRN for fatigue -
Vitamin D 4000 IU daily
Examination: -Alert, oriented, normalcognition-Visualacuity: 6/6bilaterally,
no RAPD - Motor: Normal tone, power 5/5 throughout - Reflexes: Brisk
throughout, bilateral flexor plantar responses - Sensation: Reduced pin-prick
sensation over right L4/L5 dermatome - Coordination: Intact - Gait: Normal,
including tandem
Investigations: - MRI brain and cervical spine (22/02/2025): One new T2
lesion in right centrum semiovale. No enhancing lesions. Otherwise stable
compared to previous scan (08/2024). - Blood tests: FBC, U&Es, LFTs normal.
B-cell count remains suppressed.
Assessment: Ms. Jones is experiencing a mild relapse of her RRMS with sensory
symptoms and increased fatigue. MRI shows minimal new disease activity with
one new non-enhancing lesion.
Plan: 1. Mild relapse - manage conservatively without steroids given limited
impact on function 2. Continue ocrelizumab - next infusion due March 2025 3.
Increase modafinil to 200mg morning if needed for fatigue 4. MS nurse telephone
1
follow-up in 2 weeks 5. Neurology clinic review in 6 months with repeat MRI
before appointment 6. Patient advised on relapse management and when to
contact MS team 7. Provided information on fatigue management strategies
Ms. Jones understands the assessment and plan. Reassured about continued
disease-modifying therapy effectiveness despite mild breakthrough activity.
Yours sincerely,
Dr. Michael Chen Consultant Neurologist GMC #: 7123456
cc: Patient, MS Specialist Nurse
THIS DOCUMENT IS FOR EDUCATIONAL PURPOSES ONLY